Canada markets open in 40 minutes

Small Pharma Inc. (DMTTF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.12480.0000 (0.00%)
At close: 02:06PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close0.1248
Open0.1300
BidN/A x N/A
AskN/A x N/A
Day's Range0.1248 - 0.1248
52 Week Range0.0690 - 0.6269
Volume15,930
Avg. Volume49,159
Market Cap40.587M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.0550
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Small Pharma Completes Enrollment in Phase IIa DMT-Assisted Psychotherapy Clinical Trial in Patients With Major Depressive Disorder

    Dosing for primary endpoint now completeLONDON, Sept. 19, 2022 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a biotechnology company focused on short-acting psychedelic-assisted therapies for mental health conditions, today announces that it has completed enrollment in the Phase IIa clinical trial of its intravenous (“IV”) formulation of N, N-dimethyltryptamine (“DMT”) candidate, SPL026, with psychotherapy for the treatment of Major Depressiv

  • GlobeNewswire

    Small Pharma Enters Into Automatic Share Purchase Plan

    LONDON, Sept. 13, 2022 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a biotechnology company focused on short-acting psychedelic-assisted therapies for mental health conditions, today announced that it has entered into an automatic share purchase plan (the “ASPP”) with Eight Capital (the “Broker”) in order to facilitate repurchases of the Company's common shares (the “Shares”) under its previously announced normal course issuer bid (the “NCIB

  • GlobeNewswire

    Small Pharma to Participate in Upcoming September Investor Conferences

    LONDON, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a biotechnology company focused on short-acting psychedelic-assisted therapies for mental health conditions, announces that George Tziras, Chief Executive Officer and Dr. Carol Routledge, Chief Medical and Scientific Officer, will participate in upcoming investor conferences this September. Details of the sessions are as follows: H.C. Wainwright 24th Annual Global Investment